COMPANY

Advancing the science.
Building the next medicines.

Metallomix develops pharmaceutical platforms to address unmet medical needs by investigating metal biology of the underlying diseases.

WHO WE ARE

Driven to make
a difference

Metallomix systematically invents and builds therapeutic platforms using its proprietary biotechnologies encompassing the metallome modulation. Each platform’s development is carried forward by a dedicated Metallomix subsidiary.

Metallomix Inc.
175 SW 7-th Street
Suite 1702
Miami, Florida 33130
Fax: (305) 204-5531
eMail: Admin@Metallomix.com

OUR HISTORY

Metallomix Inc. (formerly Nomax Therapeutics, Inc.) was incorporated in 2021 to spin off the drug development business of our affiliate, Vector Vitale LLC. Vector Vitale historically coordinated enriched-isotope sourcing, manufacturing of KLS-1 and other ISM molecules, and research through preclinical and clinical development. As these activities expanded, separating drug development from isotope procurement and manufacturing became a strategic priority.

Under this model, Metallomix focuses on innovation, clinical development, pipeline expansion and drug manufacturing, while Vector Vitale remains focused on enriched-isotope sourcing and validation to pharmaceutical grade. This division is intended to strengthen specialization, operational efficiency, risk management, regulatory oversight, and intellectual property protection, while allowing Metallomix to direct capital toward new ISM compounds and formulations rather than isotope inventories and enrichment facilities. The companies continue to collaborate under their Technology License and Collaboration Agreement, which defines their respective duties and responsibilities.

LEADERSHIP

Max Temnik, PhD

Max TemnikPhD

Founder & Chief Executive Officer

SHORT BIO

Max Temnik, PhD

Dr. Temnik is Metallomix’s founder and the original inventor of isotope-selective modulation (ISM) therapy, with a background in scientific research, entrepreneurship, and global business. Before entering biotechnology, he built a real estate development group with more than 3,000 employees and annual revenue exceeding $1.5 billion. Since 2011, he has led ISM research and development and invested his own capital in advancing the technology. At Metallomix, he combines scientific leadership with experience in international operations, acquisitions, and business expansion to advance the company’s platforms and development programs.

Sergey Gurin, MBA

Sergey GurinMBA

Executive VP and Chief Operating & Financial Officer

SHORT BIO

Sergey Gurin, MBA

Mr. Gurin is Metallomix’s co-founder, a serial entrepreneur, investor, and inventor on more than 30 patents, with over three decades of experience building development-stage companies. Since joining Max Temnik in 2021, he has contributed to key scientific research and clinical development. At Metallomix, he combines expertise in biophysics with leadership in operations, finance, intellectual property, and capital sourcing. His focus is on advancing new products and supporting the partnerships, transactions, and funding needed to translate innovation into commercial development.

Santosh Kesari, MD, PhD

Santosh KesariMD, PhD

Chief Medical Officer, Neurology & Oncology

SHORT BIO

Santosh Kesari, MD, PhD

Dr. Kesari is a board-certified neurologist and neuro-oncologist with a background in clinical care, translational research, and biotechnology. His experience includes academic appointments at Harvard Medical School and UC San Diego, and research leadership at Saint John’s Cancer Institute and Pacific Neuroscience Institute. An author of more than 500 scientific publications, reviews, and books, he brings expertise in tumor biology and treatment resistance. At Metallomix, he guides neurology and oncology development, focusing on precision therapeutic strategies that connect molecular understanding with clinical progress.

Dmytro Piliuhin, MD, PhD

Dmytro PiliuhinMD, PhD

Vice President, Clinical Development, Oncology

SHORT BIO

Dmytro Piliuhin, MD, PhD

Dr. Piliuhin is an oncology drug development physician with a background in clinical oncology, academic research, and biotechnology. At Metallomix, he provides medical and clinical development leadership, shaping the clinical strategy, trial design, indication selection, biomarker approach, and interpretation of emerging patient data. His focus is on translating tumor biology and early clinical signals into practical development decisions and a clear path toward proof of concept.

BOARD OF DIRECTORS

THE TEAM

Stanley Liang, JD, PhD

Intellectual Property

LinkedIn

Ihor Yakymenko, Pharm.D

Drug Development

Olexandra Likhova, PhD

Malignant Pathologies

Mykhailo Vlasenko, MS

CMC, Manufacturing

PRESENTATIONS

Company Presentations

Presentations on Metallomix’s company strategy, platforms and programs, and partnership opportunities will be available here.

Company overview

COMPANY PRESENTATION

Our mission, scientific direction, and company strategy.

Coming soon

Platforms and programs

Our connected platforms, lead programs, and development roadmap.

Watch now

Partnership opportunities

COMPANY PRESENTATION

IP licensing, scientific collaboration, and opportunities to work with Metallomix.

Coming soon

WE SHARE